Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI. Sonpavde G, et al. Among authors: quinn di. Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10. Clin Genitourin Cancer. 2017. PMID: 28579151 Free PMC article.
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR; California Cancer Consortium. Lara PN Jr, et al. Among authors: quinn di. Clin Cancer Res. 2003 Oct 15;9(13):4772-81. Clin Cancer Res. 2003. PMID: 14581348 Clinical Trial.
Angiogenesis-targeted therapies in prostate cancer.
Lara PN Jr, Twardowski P, Quinn DI. Lara PN Jr, et al. Among authors: quinn di. Clin Prostate Cancer. 2004 Dec;3(3):165-73. doi: 10.3816/cgc.2004.n.027. Clin Prostate Cancer. 2004. PMID: 15636683 Review.
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: quinn di. Clin Cancer Res. 2006 Mar 1;12(5):1556-63. doi: 10.1158/1078-0432.CCR-05-2074. Clin Cancer Res. 2006. PMID: 16533781 Clinical Trial.
272 results